Using FET-PET/MRI to improve treatment planning for glioblastoma patients after surgery
FET-PET/MRI Based Treatment Planning for Glioblastoma Multiforme in Post-Surgical Patients (FET-TREAT)
This study is testing whether special imaging techniques can help doctors better plan treatment for glioblastoma patients after their surgery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 15 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Sunnybrook Health Sciences Centre Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Toronto, Ontario) |
| Trial ID | NCT06451042 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients diagnosed with glioblastoma multiforme who have undergone post-maximal surgical resection. It aims to utilize FET-PET/MRI imaging techniques to more accurately assess the extent of the tumor, which is crucial for effective treatment planning. By improving the precision of tumor delineation, the study seeks to enhance patient management and potentially improve survival rates and quality of life. Participants will undergo FET-PET/MRI scans to gather data on tumor characteristics and treatment outcomes.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who have been diagnosed with glioblastoma multiforme and have undergone safe surgical resection.
Not a fit: Patients with contraindications for MRI, severe renal impairment, or those unable to comply with the study protocol may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more effective treatment planning and improved survival rates for glioblastoma patients.
How similar studies have performed: While the use of advanced imaging techniques like FET-PET/MRI is promising, the specific application in this context is novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Each participant must meet all of the following inclusion criteria to participate in this study: * ≥ 18 years of age * Diagnosis of glioblastoma multiforme * Post-maximally safe surgical resection * No prior radiation or systemic treatment for high grade glioma * Able to tolerate PET/MRI scan with intravenous contrast * Willing to provide informed consent Exclusion Criteria: All participants meeting any of the following exclusion criteria at baseline screening will be excluded from participation in this study: * MRI contraindication * Creatinine clearance \< 30mL/min * Inability to lie still for 60 minutes * Gadolinium allergy * Positive pregnancy test * Breastfeeding * Patient unable to follow the protocol for any reason
Where this trial is running
Toronto, Ontario
- Sunnybrook Health Sciences Centre — Toronto, Ontario, Canada (Recruiting)
Study contacts
- Principal investigator: Amit Singnurkar — Sunnybrook Health Sciences Centre
- Study coordinator: Amit Singnurkar, MD
- Email: amit.singnurkar@sunnybrook.ca
- Phone: 416-480-6100
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.